Neuropathy News and Research

RSS

New tool developed for dementia affected people

The elderly who suffer from dementia aren't able to say when something hurts or is sore. They may demonstrate their pain through behaviours like rocking or striking out, and we often dismiss these actions as symptoms of the dementia instead of pain, which is usually from a different problem. Arthritis, diabetic neuropathy, fractures, muscular contractures, bruises, abdominal pain and mouth ulcers are among the list of common ailments that go undetected.

2 Sep 2009

Cimzia approved for treating adult patients with rheumatoid arthritis

UCB Canada Inc. announced today that Health Canada has approved Cimzia, the only PEGylated anti-TNF (Tumor Necrosis Factor), for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA).

1 Sep 2009

Rebuilder Medical Technologies is in concluding stages of finalizing a national contract to provide billing services for all physicians

ReBuilder Medical Technologies, Inc. (Pink Sheets: RBRM) a provider of electronic treatments for the pain resulting from peripheral neuropathy and Peripheral Artery Disease today announced that it is in the final stages of negotiating a national contract to provide all physicians with billing services for Medicare claims for the ReBuilder.

29 Aug 2009

ReBuilder Medical Technologies reports 100% increase in second-quarter 2009 profits over first-quarter

ReBuilder Medical Technologies, Inc. (Pink Sheets: RBRM) a provider of electronic treatments for the pain resulting from peripheral neuropathy and Peripheral Artery Disease today announced that it has published its second quarter 09 profits and that profits are up 100% over the first quarter.

28 Aug 2009

Significant drop in prevalence of rheumatoid vasculitis between 2000 and 2001

Researchers at the University of Wisconsin School of Medicine and Public Health examined records of rheumatoid arthritis (RA) patients from the national Veterans Health Administration (VHA) system to determine the prevalence of rheumatoid vasculitis (RV) in this population. The study found a downward trend in the number of RA patients who go on to develop RV, with a significant drop of 53% among inpatients and 31% among outpatients between 2000 and 2001.

27 Aug 2009

PD2i algorithm published in Therapeutics and Clinical Risk Management can predict risk of sudden cardiac death

David H. Fater, CEO of Vicor Technologies, Inc., today announced that original research conducted using its PD2i algorithm to prospectively predict risk of sudden cardiac death was published in Therapeutics and Clinical Risk Management.

26 Aug 2009

New online educational forum for medical professionals from HMP Communications

HMP Communications, the authoritative source for education services targeting healthcare professionals for over two decades, announced it has added a new online educational forum at www.CardiovascularLIVE.com. The site offers video instruction and discussion forums for medical professionals.

26 Aug 2009

First-quarter financial results of ReBuilder Medical Technologies announced

ReBuilder Medical Technologies, Inc. (Pink Sheets: RBRM) a provider of electronic treatments for the pain resulting from Peripheral Neuropathy and Peripheral Artery Disease today announced that it has turned the corner and is now reporting profits for the first Quarter of 2009.

26 Aug 2009

Seattle Genetics completes enrollment of its pivotal clinical trial of brentuximab vedotin

Seattle Genetics, Inc. today announced that it has completed enrollment of its pivotal clinical trial of brentuximab vedotin (SGN-35) for relapsed and refractory Hodgkin lymphoma. Brentuximab vedotin is an antibody-drug conjugate (ADC) targeted to CD30 utilizing the company’s proprietary ADC technology.

25 Aug 2009

Lundbeck to launch Sabril in the US following FDA's NDA approval

Lundbeck Inc. (“Lundbeck”), a wholly owned subsidiary of H. Lundbeck A/S in Denmark (Copenhagen: LUN), announced today that the U.S. Food and Drug Administration (FDA) has granted two New Drug Application (NDA) approvals for Sabril® (vigabatrin) Tablets and Oral Solution. Lundbeck plans to launch Sabril in the United States in the third quarter.

24 Aug 2009

Managing Myeloma educational website launches forum to encourage oncology nurses to discuss myeloma challenges

Managing Myeloma (www.ManagingMyeloma.com), an accredited educational website for multidisciplinary professionals, has launched a forum designed specifically for oncology nurses. The goal of the nursing forum is to share insight about day-to-day practice challenges in caring for patients with multiple myeloma, provide updates on clinical advances, and connect with peers.

20 Aug 2009

Genentech announces Phase III study results for Avastin (bevacizumab) in combination with chemo in HER2-negative breast cancer

Genentech, Inc. today announced that a Phase III study (RIBBON 2) of Avastin (bevacizumab) in combination with chemotherapy increased the time women with metastatic HER2-negative breast cancer whose initial chemotherapy had stopped working lived without the disease worsening (progression-free survival or PFS), compared to chemotherapy alone.

18 Aug 2009

Electrodiagnostic and neuromuscular medicine featured at AANEM annual meeting

The American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) will hold its 56th annual meeting in San Diego, California, from October 7-10, 2009 at the Manchester Grand Hyatt.

10 Aug 2009

A new startup at California Nanosystems Institute

UCLA's newly launched on-campus technology incubator at the California NanoSystems Institute (CNSI) has opened lab space to MediSens Wireless, a startup company that develops and manufactures personal body-monitoring systems for medical and health applications.

6 Aug 2009

Biochemics and Pacific Pharmaceutical to collaborate on skin products

BioChemics, Inc. (BCI) has announced the signing of a research collaboration agreement with Pacific Pharmaceutical Co., Ltd, a publicly held Company in South Korea to evaluate the use of BCI's VALE® based compositions in cosmetic applications.

6 Aug 2009

New clues about the roots of neurological disease

Switching off a key DNA repair system in the developing nervous system is linked to smaller brain size as well as problems in brain structures vital to movement, memory and emotion, according to new research led by St. Jude Children's Research Hospital scientists.

27 Jul 2009

Schering-Plough expands Vicriviroc study in treatment-naive patients with HIV

Schering-Plough Corporation has announced that it has extended to stage two an ongoing Phase II clinical study with vicriviroc, its investigational CCR5 antagonist, for use in first-line therapy of adult treatment-naive HIV-infected patients with R5-type virus only. In this study, vicriviroc is being evaluated in a novel nucleoside-sparing regimen that is designed to provide additional options for treatment-naive patients in a once daily regimen, while preserving other drug classes for subsequent lines of treatment.

15 Jul 2009

DNA template could explain evolutionary shifts

Rearrangements of all sizes in genomes, genes and exons can result from a glitch in DNA copying that occurs when the process stalls at a critical point and then shifts to a different genetic template, duplicating and even triplicating genes or just shuffling or deleting part of the code within them, said researchers from Baylor College of Medicine in a recent report in the journal Nature Genetics.

22 Jun 2009

Seattle Genetics starts trial of SGN-35 for anaplastic large cell lymphoma

Seattle Genetics, Inc. (NASDAQ:SGEN), has announced that it has initiated a phase II clinical trial of SGN-35 for patients with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL). SGN-35 is an antibody-drug conjugate (ADC) that utilizes Seattle Genetics’ proprietary technology to empower antibodies by linking them to potent cell-killing drugs.

18 Jun 2009

Lyme disease emerging in Canada

Lyme disease is emerging in Canada, and is expected to increase with climate change, but effective, enhanced surveillance and clinician awareness will be key to minimizing the impact of the disease, write researchers in a review in CMAJ (Canadian Medical Association Journal).

9 Jun 2009